Corporate Planning


   Dr. Pan Aihua, Chairman of the Board of Sinobioway Group, first put forward the concept of bioeconomy in 1995. Later in 2003, he published relative papers and established the bioeconomic theory. After ten years of intensive studies, he developed a theoretical system of bioeconomy. It is mainly composed of the following ten theories: Bioeconomics, New Capital, Econo-genology, Theory of Biological Reconstruction ofAssets, Medical Model of Stock Market, Theory of Information Carrier of Life, Triad Theory, Social-genology, Theory ofAsymmetric Management Information, and The Corporate Theory of State. In addition, with the direction of his own bioeconomic theories, he created a bioeconomic model that is mainly composed of a bioeconomy community, bioeconomy incubators and the health internet of things (iHealth). Meanwhile, Sinobioway Group has developed the bioeconomic industry by applying the bioeconomic model under the guidance of bioeconomic theories.



    The bioeconomy industry refers to the industry formed based on the integrated and coordinated development of big finance, big market and big industries with the direction of the bioeconomic model under the guidance of bioeconomic theories. It is the single thorough solution to agricultural issues, which is at the core of issues related to agriculture, farmers and rural areas. By implementing the "Baiqian Wanyi" (Million-to-Trillion) Project, Sinobioway Group is vigorously developing the bioeconomy industry to create the largest agriculture group in the world. It also strives to address the food security issue by developing breeding technologies, the agricultural issues by developing the bioeconomy industry and the issues of farmers and rural areas by establishing the bioeconomy community (Sinobioway Commune).

    The bioeconomy industry refers to the industry formed based on the integrated and coordinated development of big finance, big market and big industries with the direction of the bioeconomic model under the guidance of bioeconomic theories. It is the single thorough solution to agricultural issues, which is at the core of issues related to agriculture, farmers and rural areas. By implementing the "Baiqian Wanyi" (Million-to-Trillion) Project, Sinobioway Group is vigorously developing the bioeconomy industry to create the largest agriculture group in the world. 



   By carrying out the "Baiqian Wanyi" (Million-to-Trillion) Project that focuses on the development of biopharmaceutical research, health management and health services, Sinobioway Biomedicine Group aims to establish the largest medical group in the world to address problems in the medicine (health) sector faced by Chinese.

Generic Drugs
Sinobioway Group will focus on bio-similar drugs and build the world’s largest manufacturing base of antibody drugs in Hefei City (100 GMP production lines)

New Drugs
New Drugs: by taking advantage of the unique strengths of China and the Group, Sinobioway Group will establish a high-efficiency new drug R&D system to industrialize valuable new drug findings around the world; integrate global medical resources to build a new drug expressway. The company aims to build a high-efficiency new drug R&D system by 2025, obtain the approval of about 25 new drugs per annum, reduce the average R&D costs of new drugs to below 30 million US dollars, and shorten R&D duration to around eight years.

Traditional Chinese Medicine (TCM)
⑴ Chinese Traditional Patent Medicine: build the world’s largest TCM manufacturing base in Tang County, Baoding City, Hebei Province (100 GMP production lines)
⑵ TCM formula particles: build the largest TCM formula particles manufacturing base in Tang County, Baoding City, Hebei Province. (500 kinds of TCM formula particles)
⑶ Geo-authentic Crude Drugs: by implementing the plan of Whole-range Quality Control of Chinese Herbal Medicine Plantation (SGAP), Sinobioway Group has built a tractable system of geo-authentic crude drugs in an effort to promote the establishment of a national testing center and integrate TCM resources to build a top TCM drug brand. In the mean time, by taking advantage of the Group’s unique strengths, the company plans to build in the form of alliance 100 planting bases of over 500 most common varieties to become the largest producer and supplier of geo-authentic crude drugs.

    Sinobioway Group has established the health internet of things (iHealth) by integrating modern scientific and technological achievements, which can realize online health monitoring. iHealth is mainly composed of four parts: life information transducers, a satellite navigation system, information processing center and a health service system. The system is capable of achieving all-day online health monitoring and management of human bodies. First, main health information is collected via sensors (such as pulses, blood pressure, body temperature, electrocardiogram and haematological indexes); the information is then delivered to the satellite navigation system before being sent to the information processing center to direct the health service system to conduct internet health services and on-site medical services following personalized information processing. Sinobioway Group has prominent strengths in three of the four above-mentioned parts: the first is with the sensors. Ordinary sensors such as iWatch can only collect data on pulses, blood pressure and body temperature; by comparison, Sinobioway’s iHealth sensors can identify over 80 haematological indexes without drawing blood; in terms of information processing, Sinobioway’s SQLFREE intelligent non-model database exceeds the world’s fastest supercomputers such as Milky Way Ⅱ in terms of processing capacity and speed; in addition, with regard to the health service system, Sinobioway has established the dumbbell model, which provides customers with high-quality, all-round and fast health services.



    Research shows that health status of populations tends to have a dumbbell shaped distribution with pre- and post-clinical phases taking both ends (85% of people) and disease status the middle part (15% of people). Therefore, a comprehensive health service system should include pre-clinical health services, diagnosis and treatment of diseases and post-clinical health services. While diagnosis and treatment are dominated by western medicine with hospitals as the main service provider (Currently there are a total number of 27,000 hospitals in China.), pre and post-clinical health services should be strongly supported by traditional Chinese medicine (TCM). So far, however, there has been a lack of health service institutions targeting these two groups of people. Sinobioway Group, by implementing the "Plan of Ten Thousand Centers in One Hundred Cities ", will established Sinobioway Community Health Service Center Chains to provide health services for pre- and post-clinical populations.